Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study
Alessandra Bettiol,Maria Letizia Urban,Lorenzo Dagna,Vincent Cottin,Franco Franceschini,Stefano Del Giacco,Franco Schiavon,Thomas Neumann,Giuseppe Lopalco,Pavel Novikov,Chiara Baldini,Carlo Lombardi,Alvise Berti,Federico Alberici,Marco Folci,Simone Negrini,Renato Alberto Sinico,Luca Quartuccio,Claudio Lunardi,Paola Parronchi,Frank Moosig,Georgina Espígol‐Frigolé,Jan Schroeder,Anna Luise Kernder,Sara Monti,Ettore Silvagni,Claudia Crimi,Francesco Cinetto,Paolo Fraticelli,Dario Roccatello,Angelo Vacca,Aladdin J. Mohammad,Bernhard Hellmich,Maxime Samson,Elena Bargagli,Jan Willem Cohen Tervaert,Camillo Ribi,Davide Fiori,Federica Bello,Filippo Fagni,Luca Moroni,Giuseppe Alvise Ramirez,Mouhamad Nasser,Chiara Marvisi,Paola Toniati,Davide Firinu,Roberto Padoan,Allyson Egan,Benjamin Seeliger,Florenzo Iannone,Carlo Salvarani,David Jayne,Domenico Prisco,Augusto Vaglio,Giacomo Emmi,Kais Ahmad,Mirko Beccalli,Bernard Bonnotte,Roberto Bortolotti,Adriana Cariddi,Marco Caminati,Maria C Cid,Margherita Deidda,Paolo Delvino,Gerardo Di Scala,Mara Felicetti,Francesco Ferro,Federica Furini,Elena Gelain,Giulia Ghirelli,Julia Holle,Laura Michelina Losappio,Alfred Mahr,Danilo Malandrino,Juliane Marhhold,Irene Mattioli,Laura Moi,Sergey Moiseev,Francesco Muratore,Santi Nolasco,Bianca Olivieri,Adalgisa Palermo,Francesca Regola,Oliver Sander,Riccardo Scarpa,Savino Sciascia,Elena Silvestri,Nicola Susca,Benjamin Terrier,Elena Treppo,Barbara Trezzi,Martina Uzzo,Gianfranco Vitiello,Elaine Yacyshyn,,
DOI: https://doi.org/10.1002/art.41943
2021-12-30
Abstract:ObjectiveMepolizumab proved efficacious for eosinophilic granulomatosis with polyangiitis (EGPA, former Churg-Strauss) at the dosage of 300mg/4 weeks in the randomized controlled MIRRA trial. Few successful real-life experiences with the dosage approved for severe eosinophilic asthma (100mg/4 weeks) were recently reported. We retrospectively assessed the effectiveness and safety of mepolizumab 100 and 300mg/4 weeks in a large European EGPA cohort. MethodsWe included all EGPA patients treated with mepolizumab at the recruiting centres in 2015-2020. Treatment response was evaluated from month 3 through 24 (T3-T24) after mepolizumab starting. Complete response (CR) was defined as no disease activity (Birmingham Vasculitis Activity Score, BVAS=0) and a prednisone dose ≤4mg/day. Respiratory outcomes included asthma and ear-nose-throat (ENT) exacerbations. ResultsWe included 203 patients, of whom 191 at stable dosage (158 mepolizumab 100mg/4 weeks, 33 300mg/4 weeks). At T3, 25 patients (12.3%) had a CR. CR rates increased to 30.4% and 35.7% at T12 and T24 and were comparable between mepolizumab 100 and 300mg/4 weeks. Mepolizumab led to a significant reduction in BVAS, prednisone dose, eosinophil counts from T3 through T24, with no significant differences between 100 and 300 mg/4weeks. Eighty-two patients (40.4%) experienced asthma exacerbations [57/158 (36%) on 100mg/4 weeks; 17/33 (52%) on 300mg/4 weeks]. Thirty-one (15.3%) experienced ENT exacerbations. Forty-four patients (21.7%) experienced adverse events, most being non-serious (38/44). ConclusionMepolizumab both at 100 and 300mg/4 weeks is effective for EGPA. The two dosages should be compared in the setting of a controlled trial.
rheumatology